Aug 2026· Journal of Neurology Neurosurgery & Psychiatry· 1 citation· 33 references
Medicine
TL;DR
Multiple plasma proteins are elevated in presymptomatic and symptomatic ADAD mutation carriers relative to non-carriers, and combining biomarkers may help in staging presymptomatic AD and optimise clinical trial inclusion.
Abstract
Background
Autosomal dominant Alzheimer's disease (ADAD) serves as a model for presymptomatic biomarker discovery. Characterising the temporal profile of plasma biomarker levels in presymptomatic individuals may enhance understanding of disease pathogenesis, inform future clinical trials and guide clinical interpretation.
Methods
We evaluated 124 proteins using a NUcleic acid-Linked Immuno-Sandwich Assay panel in 270 plasma samples from a longitudinal cohort study of ADAD, comprising 113 individuals (73 mutation carriers and 40 non-carriers). We determined the plasma proteomic changes that distinguished mutation carriers from non-carriers. We then used predicted age at symptom onset to determine the approximate timing of presymptomatic divergence in biomarker levels in carriers relative to non-carriers.
Results
Nine proteins (amyloid-beta 42 (Aβ42), beta-secretase 1 (BACE1), glial fibrillary acidic protein (GFAP), pTau181, pTau231, pTau217, t0tal tau (MAPT), neurofilament light (NfL) and acetylcholinesterase (AChE)) robustly differed between carriers and non-carriers cross-sectionally. Longitudinal analyses showed elevated Aβ42 levels were statistically discernible in carriers approximately 26 years before expected symptom onset. Carriers diverged from non-carriers in phosphorylated tau markers at approximately 21-24 years before expected symptom onset, total tau at 19 years, GFAP and BACE1 at 14 years and NfL at 6 years. Differences in AChE were seen in symptomatic individuals likely reflecting cholinesterase inhibitor use.
Conclusion
Multiple plasma proteins are elevated in presymptomatic and symptomatic ADAD mutation carriers relative to non-carriers. Changes in eight biomarkers occur sequentially from 26 to 6 years prior to symptom onset. Combining biomarkers may help in staging presymptomatic AD and optimise clinical trial inclusion. Further work is needed to assess how these findings generalise to non-monogenic AD.
The ATLAS study, a trial of tofersen initiated in clinically presymptomatic carriers of superoxide dismutase 1 (SOD1) variants, incorporated specific SOD1 variants and within-person NfL increases into risk monitoring and used these criteria to select participants for the randomized treatment phase.
Min Chen, He-Xian Li, Qing-Wen Jin· Diagnostics· 0 citations
Plasma biomarkers of amyloid-associated tau phosphorylation (T1) and established tau proteinopathy (T2) can approximate Alzheimer's disease stage, but whether plasma-defined stages correspond to broader biological states is unknown. In 1,035 participants from a multicentre Korean cohort, we used a 220-plex immunoassay...
Y. Gu, J. Kim, B. Kim et al.· medRxiv· 0 citations
Alzheimer’s disease (AD) and Parkinson’s disease (PD) together affect over 65 million people worldwide, yet no disease-modifying treatment exists for either condition. For decades, they were studied as separate entities, involving different proteins, different brain regions, and different clinical teams. Blood- based b...
Shiven Bansal· Journal of High School Resea...· 0 citations
ALS exhibits a measurable molecular prodrome detectable in blood years before diagnosis, and integrated proteomic and genetic profiling may support early identification and trial enrichment strategies.
S. Lehrer, P. Rheinstein· Journal of Clinical Neuromus...· 0 citations
The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.
Min-Young Noh, Wonjae Sung, Hyunkee Kim et al.· Alzheimer's & Dementia· 0 citations